Quick Answer
Chlorella Lipid Profile Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Conversely, catalase (WMD = 22.06 U/g.Hb; 95% CI: 3.19 to 40.93) increased significantly.
Key Takeaways
- 01Conversely, catalase (WMD = 22.06 U/g.Hb; 95% CI: 3.19 to 40.93) increased significantly. [Mardani H (2026)]
- 02While the evidence for BMI was rated as low, the certainty of evidence for most other outcomes was very low according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). [Mardani H (2026)]
- 03Our findings underscore the potential of Chlorella supplementation to support metabolic health in general population; however, given the overall very low certainty of evidence based on the GRADE assessment, these results should be interpreted cautiously. [Mardani H (2026)]
- 04This systematic review and meta-analysis aimed to evaluate the potential benefits of Chlorella supplementation in the general population, with a focus on its impact across a broad spectrum of health-related biomarkers and clinical parameters. [Mardani H (2026)]
The current Migaku evidence database contains 2 reusable source documents for Chlorella Lipid Profile Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- Conversely, catalase (WMD = 22.06 U/g.Hb; 95% CI: 3.19 to 40.93) increased significantly. [Mardani H (2026); evidence level 1]
- While the evidence for BMI was rated as low, the certainty of evidence for most other outcomes was very low according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). [Mardani H (2026); evidence level 1]
- Our findings underscore the potential of Chlorella supplementation to support metabolic health in general population; however, given the overall very low certainty of evidence based on the GRADE assessment, these results should be interpreted cautiously. [Mardani H (2026); evidence level 1]
- This systematic review and meta-analysis aimed to evaluate the potential benefits of Chlorella supplementation in the general population, with a focus on its impact across a broad spectrum of health-related biomarkers and clinical parameters. [Mardani H (2026); evidence level 1]
- Chlorella 5 7 8 9 10 Emerging evidence suggests that supplementation withand spirulina may be associated with improvements in metabolic parameters such as insulin sensitivity, lipid profiles, and hepatic steatosis markers while simultaneously reducing systemic inflammatory burden and oxidative stress. [Rzeski Wojciech (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources